White Paper AGA

Drug Development for Eosinophilic Esophagitis

Ikuo Hirano, Stuart Spechler, Glenn Furuta, Evan S. Dellon

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Since first characterized in 2 small case series in the early 1990s, eosinophilic esophagitis (EoE) has emerged as a commonly identified cause of esophageal symptoms in children and adults.1,2 Although several highly effectively dietary, pharmacologic, and endoscopic therapies have been reported, none is currently approved by either the US Food and Drug Administration (FDA) or European regulatory authorities. Evolving diagnostic criteria have challenged drug development, in particular the recognition of complex interactions with the most prevalent esophageal disorder, gastroesophageal reflux disease (GERD). Heterogeneity in the clinical presentations of affected children and adults has created difficulties with uniform inclusion criteria and the development of disease-specific, patient-reported outcome (PRO) instruments. Furthermore, controversies regarding the appropriate therapeutic endpoints of EoE have impeded the design of clinical trials. Despite these obstacles, collaborative efforts by investigators, industry, the FDA, and patient advocacy groups have resulted in substantial progress in drug development in EoE over the past 2 decades.3 The purpose of this article is to summarize discussions on EoE based on the 2016 Drug Development Conference sponsored by the Center for Diagnostics and Therapeutics of the American Gastroenterological Association.

Original languageEnglish (US)
Pages (from-to)1173-1183
Number of pages11
JournalClinical Gastroenterology and Hepatology
Volume15
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Eosinophilic Esophagitis
United States Food and Drug Administration
Pharmaceutical Preparations
Patient Advocacy
Gastroesophageal Reflux
Industry
Therapeutics
Research Personnel
Clinical Trials

Keywords

  • Dysphagia
  • Eosinophilic Esophagitis
  • Esophageal Stricture
  • Esophagitis
  • Food Allergy
  • Gastroesophageal Reflux Disease

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

White Paper AGA : Drug Development for Eosinophilic Esophagitis. / Hirano, Ikuo; Spechler, Stuart; Furuta, Glenn; Dellon, Evan S.

In: Clinical Gastroenterology and Hepatology, Vol. 15, No. 8, 01.08.2017, p. 1173-1183.

Research output: Contribution to journalArticle

Hirano, Ikuo ; Spechler, Stuart ; Furuta, Glenn ; Dellon, Evan S. / White Paper AGA : Drug Development for Eosinophilic Esophagitis. In: Clinical Gastroenterology and Hepatology. 2017 ; Vol. 15, No. 8. pp. 1173-1183.
@article{ab489ed7cfce4330b28ef39454a02b29,
title = "White Paper AGA: Drug Development for Eosinophilic Esophagitis",
abstract = "Since first characterized in 2 small case series in the early 1990s, eosinophilic esophagitis (EoE) has emerged as a commonly identified cause of esophageal symptoms in children and adults.1,2 Although several highly effectively dietary, pharmacologic, and endoscopic therapies have been reported, none is currently approved by either the US Food and Drug Administration (FDA) or European regulatory authorities. Evolving diagnostic criteria have challenged drug development, in particular the recognition of complex interactions with the most prevalent esophageal disorder, gastroesophageal reflux disease (GERD). Heterogeneity in the clinical presentations of affected children and adults has created difficulties with uniform inclusion criteria and the development of disease-specific, patient-reported outcome (PRO) instruments. Furthermore, controversies regarding the appropriate therapeutic endpoints of EoE have impeded the design of clinical trials. Despite these obstacles, collaborative efforts by investigators, industry, the FDA, and patient advocacy groups have resulted in substantial progress in drug development in EoE over the past 2 decades.3 The purpose of this article is to summarize discussions on EoE based on the 2016 Drug Development Conference sponsored by the Center for Diagnostics and Therapeutics of the American Gastroenterological Association.",
keywords = "Dysphagia, Eosinophilic Esophagitis, Esophageal Stricture, Esophagitis, Food Allergy, Gastroesophageal Reflux Disease",
author = "Ikuo Hirano and Stuart Spechler and Glenn Furuta and Dellon, {Evan S.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.cgh.2017.03.016",
language = "English (US)",
volume = "15",
pages = "1173--1183",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - White Paper AGA

T2 - Drug Development for Eosinophilic Esophagitis

AU - Hirano, Ikuo

AU - Spechler, Stuart

AU - Furuta, Glenn

AU - Dellon, Evan S.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Since first characterized in 2 small case series in the early 1990s, eosinophilic esophagitis (EoE) has emerged as a commonly identified cause of esophageal symptoms in children and adults.1,2 Although several highly effectively dietary, pharmacologic, and endoscopic therapies have been reported, none is currently approved by either the US Food and Drug Administration (FDA) or European regulatory authorities. Evolving diagnostic criteria have challenged drug development, in particular the recognition of complex interactions with the most prevalent esophageal disorder, gastroesophageal reflux disease (GERD). Heterogeneity in the clinical presentations of affected children and adults has created difficulties with uniform inclusion criteria and the development of disease-specific, patient-reported outcome (PRO) instruments. Furthermore, controversies regarding the appropriate therapeutic endpoints of EoE have impeded the design of clinical trials. Despite these obstacles, collaborative efforts by investigators, industry, the FDA, and patient advocacy groups have resulted in substantial progress in drug development in EoE over the past 2 decades.3 The purpose of this article is to summarize discussions on EoE based on the 2016 Drug Development Conference sponsored by the Center for Diagnostics and Therapeutics of the American Gastroenterological Association.

AB - Since first characterized in 2 small case series in the early 1990s, eosinophilic esophagitis (EoE) has emerged as a commonly identified cause of esophageal symptoms in children and adults.1,2 Although several highly effectively dietary, pharmacologic, and endoscopic therapies have been reported, none is currently approved by either the US Food and Drug Administration (FDA) or European regulatory authorities. Evolving diagnostic criteria have challenged drug development, in particular the recognition of complex interactions with the most prevalent esophageal disorder, gastroesophageal reflux disease (GERD). Heterogeneity in the clinical presentations of affected children and adults has created difficulties with uniform inclusion criteria and the development of disease-specific, patient-reported outcome (PRO) instruments. Furthermore, controversies regarding the appropriate therapeutic endpoints of EoE have impeded the design of clinical trials. Despite these obstacles, collaborative efforts by investigators, industry, the FDA, and patient advocacy groups have resulted in substantial progress in drug development in EoE over the past 2 decades.3 The purpose of this article is to summarize discussions on EoE based on the 2016 Drug Development Conference sponsored by the Center for Diagnostics and Therapeutics of the American Gastroenterological Association.

KW - Dysphagia

KW - Eosinophilic Esophagitis

KW - Esophageal Stricture

KW - Esophagitis

KW - Food Allergy

KW - Gastroesophageal Reflux Disease

UR - http://www.scopus.com/inward/record.url?scp=85028875179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028875179&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2017.03.016

DO - 10.1016/j.cgh.2017.03.016

M3 - Article

VL - 15

SP - 1173

EP - 1183

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 8

ER -